A recent UK survey has shown that with current treatments only 2.6% of patients with small cell lung cancer (SCLC) will survive 6 years. Death from SCLC does not occur after this time. This result indicates both that cure is possible and that new approaches to treatment will be necessary. For patients in the most favourable prognostic categories more intensive chemotherapy regimens (which are already capable of producing complete response rates of up to 50%) may improve results.
Intensive treatments using autologous bone marrow transplantation have, so far, been disappointing. Weekly intensive regimens can be given safely and give very high response rates.
Even when chemoresistant, SCLC remains radiosensitive. Systemic radiation may be a useful means of consolidating treatment in patients responding completely to chemotherapy. As a result of international collaboration, membrane antigens have been defined on SCLC which are potential candidates for radiolabelled antibody targeting. The most immunodominant has been designated cluster 1 and is now known to be the neural cell adhesion molecule N-CAM.
The growth of SCLC can also be slowed by blocking the autocrine growth stimulatory effect of gastric-releasing peptide (GRP) . GRP is one of a family of molecules which bind to SCLC surface membrane and whose actions may be interrupted by antagonists binding to specific receptors.
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Biological and clinical implications of physical dose optimisation in radiotherapy H. Bartelink
The Netherlands Cancer Institute, Amsterdam, The Netherlands Recent developments in radiotherapy, such as multileaf collimators, three-dimensional treatment planning systems or high energy electron irradiation, have led to a new era in radiotherapy. These developments allow administration of higher doses at primary tumour sites with equal or even lower radiation doses in the surrounding normal tissues. It is hoped that these efforts of improving the treatment procedure will lead to an increase in cure rate. New forms of therapy, however, always carry with them the risk of serious complications. A large increase of the complication rate can occur due to small errors as the dose-effect curves for normal tissue complications are much steeper than those for tumour. New methods for patients' daily set-up and control procedures have to be introduced in the clinic to ensure that the intended more precise radiation therapy is carried out according to treatment plan. For selection of the optimal treatment plan new criteria have to be developed to estimate the gain and the risk of new ways of treatments. These selection criteria for choosing the optimal treatment plan should be based upon In recent years, the aspect of the malignant phenotype which has received most attention is growth and proliferation; the differentiation of tumour cells has, until recently, been relatively neglected.
Differentiation in malignancy can be approached on several different levels. As its simplest level, the behaviour of a tumour can often be predicted by its differentiation pattern; an example is that tubule formation in carcinoma of the colon is an independent variable in predicting metastatic behaviour. But now the factors which determine tubule formation in carcinoma of the colon are becoming recognised at the cell biological and molecular genetic level.
The malignant change itself can be regarded as a defect in differentiation: carcinomas contain terminally differentiated cells, and indeed these can be induced by modulating the growth conditions. Both these considerations point to the conclusion that the malignant phenotype is not immutable, even in solid tumours, and that further understanding of the biological basis of differentiation in normal and malignant cell (TRUS) . Yet the prospect of using these techniques in widespread screening or early detection programmes has generated considerable controversy. Both the efficacy of these techniques and the necessity for early detection of this slow-growing cancer have been seriously questioned. Because of the remarkably high prevalence of cancer in the prostate found at autopsy of men who die of other causes, the slow progression rate of the tumour, and the advanced age of men diagnosed with the disease, patients with prostate cancer are often said to be more likely to die with rather than oftheir disease. On the other hand, once prostate cancer is diagnosed -whether by digital rectal examination, the pathological examination of the tissue from transurethral resection of the prostate (TURP), or the development of symptoms -treatment has been generally unsuccessful in controlling the disease except in its very early stages. With 28,500 men dying of the disease in the USA this year, the need for earlier detection seems evident.
This paper will review: (1) the results of treatment trials for early stage prostate cancer; (2) the natural history of the disease; and (3) the features of 'clinical' and 'autopsy' prostate cancer, all of which together provide a rational basis for the early detection that is essential if the mortality rate from prostate cancer is to decline. Autologous bone marrow transplantation is a tool to increase the dose-effect relationship in cancer therapy. In lymphomas, BMT is able to cure 70-75% of patients in partial response after induction therapy and 40% of patients still sensitive to rescue protocols at time of relapses. Primary refractory patients and resistant relapse patients are not curable yet. Addition of interleukin-2 post BMT could be a discussion to improve results for these patients.
Bob Champion Cancer Trust
In solid tumours encouraging results have been reported for neuroblastoma in children and testicular cancer in adults. However, ABMT is still an experimental procedure in this field and future directions will be reviewed.
Oral presentations
New approaches in oncology One hundred and sixty-eight patients were recruited into a randomised trial of d(l 5) + Be fast neutron therapy compared with 4MV photons in the treatment of locally advanced squamous cell carcinoma of the head and neck. Results with a minimum of two years' follow up were reported in 1987 (Duncan et al. (1987) , Int. J. Radiat. Oncol. Biol. Phys., 13, 171).
In May 1989 five-year follow-up became available for all patients. The five-year survival rate for neutrons is 23.5% and for photons 33.8% (P = 0.085). The disease-free survival for neutrons is 18.8% and for photons 30%.
Late grade 4/5 morbidity associated with neutrons exceeded that of photons. Relapse of head an neck cancer with a fixed node mass following a neck dissection and radical radiotherapy is associated with a very poor prognosis. Where complete surgical clearance is unattainable these patients have been regarded as unsalvageable. We report the results of treatment of 27 such patients, median age 61.5 years. In an effort to improve these results 17/27 patients were treated with a combination of surgical resection, interstitial '92ir implant and repair of the defect by a myocutaneous flap. Six had been treated by surgery and implant without resurfacing, and four with implant alone. Seven patients had a laryngeal primary, six oral cavity, two oropharyngeal, two hypopharyngeal and 10 other sites. The median interval between initial irradiation and the implant was 16 months and median total dose received by the 27 patients was 102.8 Gy (range 89-128 Gy). Five of six patients treated without resurfacing developed soft tissue necrosis, most healing spontaneously. The median implant dose used was 43.4 Gy (range 30-60 Gy) but since no complications have developed where a myocutaneous flap was used an implant dose of 50 Gy is now routine. The four patients not having surgery had persistent disease after treatment: one whose tumour was only debulked relapsed at the implant site and in the other neck. Of the remaining patients seven remained disease-free, four developed metastatses, two relapsed at the implant site alone, six outside the implant site and one at both sites. The median survival and disease free period of those having surgery are 11.25 months and 10.7 months respectively. The use of a myocutaneous flap and 192Ir afterloading following excision is a potentially valuable method of treating these difficult problems.
Hydralazine increases blood flow through human lung tumours N.P. Rowell, B. Cronin, V.R. McCready & A. Horwich The Royal Marsden Hospital, Sutton and MRC Radiobiology Unit, Harwell, UK. Hydralazine has been shown both to reduce tumour blood flow and to potentiate the cytotoxicity of melphalan and the bifunctional nitroimidazole RSU 1069 in mice. In order to determine whether such a strategy has clinical potential, the effects of hydralazine on blood flow through human tumours were investigated in fifteen patients with carcinoma of the bronchus (mean age 67; range 52-75 years) who received a single oral dose of hydralazine in the range 0.37-2.26 mg kg-' according to age, acetylator status and an escalating dose schedule. Tumour blood flow was assessed by single photon emission computed tomography (SPECT) performed ten minutes following intravenous 99Tcm-HMPAO on two occasions 4 -8 days apart, the second being performed 60 min after hydralazine. Blood pressure and cardiac output were measured non-invasively and repeatedly throughout.
Hydralazine caused a 25% increase in tumour blood flow (P = 0.065), with a trend for greater increases to occur in patients sustaining greater falls in peripheral resistance. Tumour vascular resistance (calculated from blood pressure and estimates of blood flow) fell, indicating active vasodilation in arterioles supplying tumours. Common symptoms in higher doses were giddiness, palpitations and facial flushing. Doses greater than 1.5-2.0 mg kg-' were poorly tolerated. Allowing for extensive first-pass metabolism in the liver, these doses are equivalent to only a fraction of those used in animal studies.
High dose melphalan improves the prognosis in advanced neuroblastoma: results of a randomised study of 'ENSG -1' J. Pritchard We wished to investigate the value of high dose melphalan (HDM) as 'consolidation therapy' in children with advanced neuroblastoma. One hundred and thirty patients over 6 months of age with Evans stage III or IV tumours, consecutively referred to 16 centres, were given 3-4 weekly 'OPEC' induction therapy and, where possible, had the primary tumour resected. Ninety patients (69.2%) achieved complete response or good partial response (disappearance of all evidence of secondary deposits and shrinkage of primary by > 50% in each of three dimensions), and were eligible, after stratification by stage and centre, for randomisation either to one high dose of melphalan (180 mg m2) with autologous bone marrow rescue or to no further treatment. Because of non-compliance by some parents and physicians only 65 patients were actually randomised. Despite serious toxicity including two treatment-related deaths, patients in the HDM group had better event-free survival (median 24 vs 8 months; 2-sided P = 0.045, log rank) than those in the 'no further treatment' group. Results were similar for children with the worst prognostic features, i.e. those with stage IV disease aged over 12 months at diagnosis (disease-free survival median 22 vs 5 months; two-sided P = 0.025, log rank). Though longer follow-up is needed to establish the pattern of long-term survival we conclude that HDM is of benefit to children with advanced neuroblastoma who have achieved complete or good partial response after OPEC Sixty-seven of the district's 121 GPs and 33 of 80 community nurses replied to a questionnaire regarding breast cancer management. With regard to the aims of local therapy 20% of GPs held the view that it was to increase survival, 45% that it was to increase disease-free survival and 30% that it decreased local recurrence. With regard to follow up a majority of both GPs (67%) and community nurses (60%) felt the aim was early detection of metastases. Views on the side-effects of radiotherapy and chemotherapy were also explored with some unexpected findings. In particular 17% of GPs and 24% of community nurses felt that hair loss was an expected side effect of radiotherapy treatment.
The results of this survey in one district show the lack of any local consensus or recognised 'specialist' surgeon and point to some misunderstandings amongst community nurses and GPs about aims and side effects of breast cancer treatment. Forty-five patients with primary lung cancer were interviewed within 3 months of their diagnosis to determine how they perceived their illness and how their perceptions compared with those of their attending physicians. All of the 45 patients knew that they had lung cancer. Twenty-six of the 45 correctly recognised the extent of their disease as localised, regional or metastatic. However, 16 of 25 patients with regional disease, and two of the 15 patients with metastatic disease thought that the cancer was localised. Two of the 11 patients being treated with curative intent thought that the treatment was palliative only, and nine of the 34 patients being treated palliatively believed the treatment intent was cure. Seventeen of the 34 incurable patients thought that they had a chance of being cured and 15 of these thought that the probability of being cured was at least 50%. In every case the doctors stated that they had accurately informed the patient about the probability of cure and that they thought the patient accurately understood the prognosis. No Since February 1986, the Clatterbridge cyclotron has been used to conduct clinical trials in which patients are randomised to treatment with either photons or high energy neutrons. The neutron beam is produced by bombarding a beryllium target with 62 MeV protons, and the treatment unit consists of a variable collimator mounted on a fully isocentric gantry equipped with both wedges and field shaping facilities. The depth of the 50% isodose is 16 cm for a 10 x 10 cm field which is compatible with that of an 8 MV linac. Careful quality control has been applied to both the beam parameters which affect the dose distribution and also the patient dose distributions. A review of the quality assurance results showed that the random uncertainties in calibration, field flatness, field symmetry and beam penetration contributed to a total random uncertainty of 1.5% to the tumour dose. For the first 100 patients, the comparability of neutron and photon treatment plans was one of the criteria for entry to the trials. A dose variation of ± 7% throughout the target volume was the limit of acceptability, and most plans had variations of less than ± 5%. An initial comparison of the phase 1 treatment volumes for sites in the pelvis resulted in values of approximately 3,300 cm3 for both neutron and photon treated patients. It is hoped that the improved dose distribution combined with advances in the localisation of disease will lower the morbidity of neutron therapy. Although information about prognosis and tumor response is readily available for groups and subgroups of patients with the common malignant diseases, there is no information about oncologists' ability to predict what will become of individual patients. We prospectively obtained attending physicians' estimates of probability of cure for 98 patients undergoing treatment at the Kingston Cancer Clinic. These predictions were subsequently correlated with the outcome of the disease process. The two-year survival rate of 56 patients undergoing curative treatment, and of 42 patients undergoing palliative treatment were 66.9% and 11.4% respectively (P <0.0001). The two-year disease free survival of a subgroup of 28 patients, whose predicted cure rate was >0% .50%, was 35.8% compared to 85.6% for a subgroup of 28 patients whose predicted cure rate was >50% (P <0.0001). There was a significant correlation between predicted probability of cure and complete response (CR) rates (predicted cure rate >0 < 30%, CR = 62.5% and predicted cure rate > 30%, CR=100%; P<0.01).
Doctors estimated the survival of 39 of the 42 incurable patients as 0-3 months, 4-6 months, 7-12 months, I -2 years or greater than 2 years. Twelve died within the predicted interval, 12 died earlier and 15 lived longer than expected. Patients expected to live for less than 6 months had a median survival of 238 days compared to 414 days for those expected to live for more than I year. The variance of survival within each group was very large and this difference did not reach statistical significance (P = 0.1). The accuracy of survival predictions was independent of the doctor's age, sex or specialty training. Oncologists' predictions of curability correlate well with both complete response rates and 2-year survival rates, but estimates of duration of survival for individual incurable patients are usually inaccurate. 3D treatment planning enables the calculation of integral dose-volume histograms (DVH) which give the true picture of dose distribution in normal tissue. We analysed the DVH in normal brain of eight patients undergoing localised external beam radiotherapy for CNS tumours. A mean of 43% (24-57%) of normal brain volume received more than 50% and mean of 22% (9-38%) received more than 85% of the maximum tumour dose. The addition of customised shielding blocks using a 3D planning facility led to a mean reduction of 13% and 8% of the normal brain volume irradiated to more than 50% and 85% of the maximum tumour dose respectively.
Dose-volume histograms demonstrate that surprisingly large volumes of normal brain receive clinically significant doses of radiation despite localised treatment technique. Although the use of customised shielding blocks reduces the amount of normal brain irradiated, the reduction is unlikely to be sufficient for a significant improvement in therapeutic ratio. Further improvement may only be achieved with more localised delivery of radiation.
Our results show that the oc/p ratio calculated from the LQ fit to the acute survival curves varied from 11 to 46. In contrast, when the values were obtained as described above, we came to the startling conclusion that the cx/p ratio is constant with a value of 10.3 ± 1.7. Kaposi's sarcoma is diagnosed in almost 40% of patients with AIDS at our institution. One hundred and ninety-four cases were diagnosed by the end of 1988. These patients have a median survival of 20 months, and where the cause of death is known 38.6% died directly due to the Kaposi's sarcoma and in a further 11.4% it was considered to be an important contributing factor. We aim to palliate the disease where indicated.
The indication for radiotherapy in our department has been for cosmesis in 63.5% and for pain and functional complaints in the remainder. The Some investigators have correlated an enhancement of class 1 MHC by interferons with increased resistance to NK lysis, and suggested that this is the mechanism of enhancement of metastatic potential. This is unlikely to be the case in our model, since both interferons equally enhance class 1 MHC. Germ cell tumours are striking examples of how normal differentiation can be disrupted by malignant transformation. Instead of producing gametes, these tumours give rise to tissues exhibiting features of embryonal development. Cell lines derived from both murine and human germ cell tumours can be induced to differentiate in vitro by exposure to retinoic acid. In order to investigate the molecular basis of how genes are regulated during teratocarcinoma stem cell differentiation we have stably introduced test genes into undifferentiated mouse F9 teratocarcinoma cells using the episomal vestor L factor, a plasmid related to polyoma virus that replicates extrachromosomally as closed circles of DNA (Nashimori et al., Mol. Cell Biol., 8, 2097 Reconstruction of the head and neck has to encompass the functions of the part: respiration, mastication, swallowing, speech and cosmesis. Following the excision of tumours, restoration of function requires the replacement of that part which has been removed. The concept of reconstruction has changed in recent years as knowledge of the blood supply to the skin has reduced it from a multistaged procedure to a single operation, through the use of myocutaneous and free flap transfer.
Problems of colour match, skin quality and function bedevil the reconstructive surgeon. The introduction of distant flaps to the face results in a patch-like deformity. The thickness of the subcutaneous tissues may vary giving problems of bulk. External skin is frequently used to replace the mucosa; in this situation the flap will be non-sensory, nonsecretory, possibly hairy and immobile, whereas the mucosa is sensate, does secrete, does not grow hairs and is mobile.
Oral and pharyngeal reconstruction must be considered as a three-dimensional concept. Frequently a single flap is used in the repair, which may result in the limitation of function. Examples will be shown to illustrate the modern concept of reconstruction with particular reference to the single staged compound flap repairs. Germany, Winkelmann (1983) resected the tumour approximating the residual bone and with lesions of the lower limb rotated the distal part through 180 degrees so that the ankle could be employed as a knee joint (rotation turniplasty). All these methods were excellent in concept; the disadvantages were the length of time that elapsed before the limb could function. Function was necessarily of limited achievement.
In this country, Burrows et al. (1975) had already had experience in the treatment of chondrosarcoma and extensive benign tumours, replacing the affected bone and associated joint with an internal prosthesis. With the advent of bone cement more sophisticated fixation of the prosthesis was achieved. In consequence, over 1,000 bone tumours have now, in the short-term, been successfully treated in the two supra-regional centres.
Today, due to the use of cytotoxic therapy in conjunction with surgery, the survival rate of patients with Ewing's sarcomas and osteogenic sarcomas is in the region of 60%.
This particular method for treatment has certain disadvantages. Prosthetic loosening and prosthetic fracture are now essentially minor problems, but the risk of infection in patients who are immunologically compromised as a sequel to cytotoxic therapy must obviously remain high and, although the majority of infections respond adequately to antibiotic therapy, 2% of patients will develop extensive osteomyelitis necessitating amputation. The advantage of this form of management is that the patient can be rapidly rehabilitated to near normal function and the body image is maintained, a feature of some consequence to the adolescent and young adult. Reconstructive urology in this context means provision of a neo-bladder which is continent and which is usually emptied by intermittent clean self-catheterisation (ICSC). Experience in children and adolescents has shown that no patient need have an external urinary diversion with a bag. The question now arises when and how the same should be applied to the cancer patient. Reconstruction should not be confined to a named operation such as the 'Kock', the 'Indiana' or the 'Mainz'. Three mutually independent components are necessary: a container for the urine, a means to conduct the urine to the surface and a continence mechanism. One or more items for each of the components may be selected from the lists in the Immediate reconstruction following either curative or palliative cancer surgery offers enormous advantages. The knowledge that a safe, simple and reliable method of reconstruction is available allows the surgeon to resect tumours with a wide margin of clearance. This is particularly important in the treatment of post-irradiation recurrent tumours where the anatomical limit of the tumour may be difficult to define and where surrounding disease-free but irradiated tissues heal notoriously badly. The transfer of healthy, unirradiated and well-vascularised tissues into an irradiated wound allows wound closure without tension, accelerates and greatly improves the chances of primary healing, protects against infection and fills spaces where damaging haematomas might have collected. New reconstructive techniques which have come into common use over the past decade have enhanced the scope of surgical oncology. Multistaged reconstructive techniques are rarely necessary and patients can be offered immediate reliable reconstruction thereby reducing morbidity and time in hospital. The purpose of this symposium is to describe the reconstructive techniques available and illustrate their place in patient management. Skin and soft tissue is the main requirement following ablative surgery and the various myocutaneous transposition techniques will be described but occasionally blood vessels, nerves, bone and joints need reconstruction. Reconstruction is most often required for post-irradiation recurrent tumours and this presentation will describe reconstructive The purpose of this study was to examine the late effects of cerebral irradiation. The aim was to establish whether particular parts of the brain showed a predilection for radiation damage; and if damage was demonstrable ascertain if chronic ischaemia played a role in its pathogenesis.
Five patients with gliomas (two grade III astrocytoma, two grade II astrocytoma and one oligodendroglioma) were studied at least 12 months after irradition (mean 18 months). The patients tumour volume received 60 Gy in 30 fractions over 42 days. The technique of positron emission tomography was used to study regional cerebral blood flow (rCBF), regional metabolic rate for oxygen (rCMRO2) and fraction of oxygen extracted from the arterial blood (rOEF). There were marked regional variations.
Our results show that abnormal brain expresses late radiation damage more readily than normal brain and white matter more readily than grey matter. Ischaemia (inappropriately low blood flow for local metabolic demands) cannot be the main reason for the late radiation effects because the rOEF lay within the normal range (0.3-0.5).
CBF CMRO2
(ml 100 ml-min-') OEF (ml of 02 l(J ml0 I min-') Twelve patients had complete, 30 partial excision and 10 biopsy only; 41 patients received postoperative radiotherapy (RT): 28 received RT to the primary site alone (5OGy), 13 had whole neuraxis RT (30-35 Gy) followed by boost (15) (16) (17) (18) (19) (20) . Four patients also received adjuvant chemotherapy.
Thirteen of 40 patients with residual disease progressed. The 5 and 10-year progression-free survival (PFS) were 73%. Following complete excision the progression rate was low. PFS was worse with high compared to low grade tumours. The 10-year cause specific survival was 73%. Early carcinoma of the cervix can be treated by surgery or radiation alone or by a combination of both. This paper describes a large series of patients treated by preoperative intracavity irradiation followed by immediate Wertheim's hysterectomy. After initial staging, a Curietron after-loading technique is used: a plastic intra-uterine tube is placed in the cervix and is attached to a vaginal applicator. The whole apparatus is held in place by a harness attached to a body corset. X-ray pictures are taken (using dummy wires) on a treatment simulator in the radiotherapy department. The patient is then connected to the Curietron and stays in a single fully-protected room for the duration of treatment. We have seen generation of lymphokine activated killer (LAK) activity after intraperitoneal infusion of blood lyphocytes, obtained by leukopheresis, incubated in vivo with simultaneously administered doses of recombinant IL-2 (rIL-2) increasing from 11.5 to 135,000 U kg-' h-' for 10 days.
This was followed by transfer of LAK cells from the peritoneum by Denver shunt. Mild pyrexia (n = 7), malaise (n = 7), anorexia and nausea (n = 4) were observed. There was no evidence of capillary leak syndrome, however, and all patients developed an early lymphopenia and anaemia which required transfusion of packed cells in five cases. Platelets and clotting activity remained normal but an eosinophilia and neutrophilia were observed. Lymphocyte subset markers and natural killer activity to K562 targets were studied serially during the 10-day infusion period by flow cytometric analysis. A significant increase in NK (CD16 +) and activated (CD25 +) cells was observed in the peritoneal cavity and NK cell activity increased in cells from both the peritoneal cavity (7-33%) and blood (10-15% An earlier study of platinum uptake in the kidney following cisplatin chemotherapy reported, unexpectedly, very high kidney lead levels in four of 10 subjects, two of whom definitely had occupational lead exposure, one with exceptionally high bone lead, and a third with probable exposure. This gave rise to the hypothesis that cisplatin could mobilise lead from the skeleton. We report here two further, independent, investigations performed at Swansea and Birmingham, the object being to establish if lead mobilisation was a clinically significant hazard to patients treated with conventional doses of cisplatin. Each centre used a different X-ray fluorescence system to monitor renal lead levels on a total of 17 subjects (11 male and six female) undergoing cisplatin chemotherapy for a variety of solid tumours. Whole blood, serum and urine lead concentrations were also monitored before and after chemotherapy. In contrast to the earlier study, none of these subjects was known to be occupationally exposed. Pre-treatment values of whole blood and urine were all within their normal ranges for non-occupational exposed subjects (<30 tg d1-' and 50gSg 24 h-respectively), as were bone lead levels. Following chemotherapy, renal accumulation of lead was observed in only one subject, who showed transitory levels up to 100 fig Pb g-' kidney tissue, much lower than the high levels reported previously. This is consistent with the blood, serum and urine analyses which, where above atomic absorption spectrometry detection limits, showed only minor changes in all subjects. We conclude that any lead mobilisation following cisplatin chemotherapy is unlikely to pose a major hazard to most patients, but that the possible significance for those exposed to lead and having high skeletal lead burdens remains to be determined. Irradiation of a 1.9 cm long mouse right hemithorax field (RHT) to 14 Gy and 18 Gy with 250 kV X-rays produced a rise in breathing rate which was dose-related and maximal at 14-18 weeks. To investigate the interaction with cytotoxic drugs, the maximally tolerated dose of cytotoxic drug was administered intraperitoneally 45 min before 14 Gy RHT irradiation. Cyclophosphamide 100 mg kg-' accentuated and accelerated the rise in breathing rate. Ifosfamide 300 mg kg-' had no such effect. BCNU delayed the rise in breathing rate to after 26 weeks. Busulphan 30 mg kg-' appeared to abolish the effect of irradiation, but this was due to the DMSO vehicle. The following cytotoxics had no effect; doxorubicin 6mg kg-', carboplatin 100mg kg-', vindesine 4mg kg-', vinblastine 4 mg kg-'.
In conclusion, this is a simple and convenient screening test for cytotoxic irradiation lung interactions, yielding qualitative information on the presence of an interaction, and further information on the time course of the response. The effect of temperature on doxorubicin (ADM) accumulation and cytotoxocity was studied in vitro in the human ovarian carcinoma cell line A2780-9S and in its multidrugresistant variant A2780-AD645. Intracellular ADM levels were measured by flow cytometry and ADM cytotoxicity was measured using a clonogenic assay.
ADM cytotoxicity was markedly enhanced in both cell lines when cells were exposed to the drug at elevated temperatures. Initial rates of ADM influx were similar in the two cell lines and both lines showed a similar large increase in initial rate of influx with increasing temperature. Little efflux of ADM occurred in the sensitive cell line, but in the resistant cell line intracellular ADM levels decreased to approximately 50% Recently the central importance of the extracellular matrix (ECM) in the control of growth and differentiation has begun to be appreciated. In particular, the proteoglycan content of the ECM is known to be of importance, for example in the attachment of differentiating cells to stromal cells, the binding of locally released growth factors, and the guiding of the normal pathway of migration in certain embryonic cells.
We report on a new extracellular matrix proteoglycan produced by human embryonal carcinoma cells (EC) and recognised by the monoclonal antibody GCTM-2. Immuno Repair capacity has been assessed using a viral reactivation assay in which cells are infected with irradiated virus and the ability of the cells to repair the damaged virus is measured by counting the number of cells containing proliferating virus.
Five cell lines have been examined. Two radioresistant bladder carcinoma lines (MGH-U1 and RT1 12) proved to reactivate the virus to a greater extent than the more sensitive neuroblastoma lines (HX142 and HX138). However, the most radioresistant line, HeLA, was least proficient in the virus assay.
The level of induced DNA double strand breaks has been measured in nine human tumour cell lines using neutral filter elution. A broad spectrum of induction curves was found and it was evident that the level of damage was greater in the more sensitive cell lines.
We therefore conclude that while no Hypervariable minisatellite DNA probes 33.6 and 33.15 have been employed in a novel way in a group of patients receiving combination chemotherapy in the treatment of lymphoma. The multi-locus nature of these probes allows simultaneous observation of over 60 different sites in human genomic DNA, enhancing the possibility of observing change.
In three patients out of 10 already studied, changes have been observed in their peripheral leukocyte-derived DNA fingerprint at some point after starting treatment. Changes involve both the loss of bands present in pre-treatment samples and the appearance of novel bands.
Care has been taken to consider possible mechanisms whereby the changes may have arisen spuriously, or may represent artefacts generated by the fingerprinting technique. We conclude that the changes observed are unlikely to represent any of these mechanisms, and that they may represent site-specific modification of the DNA by one or more of the agents used in chemotherapeutic regimes.
We will explore possible mechanisms by which these changes may have arisen, and discuss possible implications for risk of therapy-related malignancy This method provides an early prediction of both sensitivity and resistance in individual patients. The repeatability and speed enables sequential testing throughout the course of the disease allowing for rapid response to changes in drug sensitivity. Data about hypoxia fractions in human tumours is circumstantial because of the limitations of current methods for measuring oxygen. A prototype printed circuit was designed with the dual intention of establishing whether: (1) the materials and fabrication techniques required were biocompatible and (2) such a circuit would be capable of measuring a biologically generated potential.
The circuit, etched on glass so that the growing cells could be visualised, was designed with 52 electrodes, 4 x 4 jim size. They were arranged in quadrants 20 jim apart to correspond with the approximate size of tumour cells in culture. Three cell lines, Chinese hamster ovary, a mouse fibroblast and a mouse neuroblastoma line will grow normally on the circuits as demonstrated by standard growth curves. S.e.m.s will be presented showing the complexity of the cell/sensor interface.
To test the circuit's ability to pick up a biologically generated signal frog cardiac muscle which was visibly contracting was placed onto the circuit. Cardiac potentials were recorded from each terminal providing data from which the signal/noise ratio could be calculated.
We have therefore integrated 21 oxygen sensors and three thermistors into the circuit to measure oxygen in vitro and have designed a multichannel silicon probe for in vivo use. This probe will be implanted into a growing tumour to build up a dynamic three dimensional blueprint of oxygen and temperature. Five per cent 5-fluorouracil cream (Efudix) is used to treat selected neoplastic and pre-neoplastic cutaneous lesions. A frequent indication for treating cutaneous AIDS-related Kaposi's sarcoma is for cosmesis. Localised lesions are often treated by radiotherapy or by intralesional cytotoxic chemotherapy. The self application of a cream to treat early cosmetically unacceptable sites of disease would be an attractive therapy for this group of highly motivated patients. We are conducting a pilot study of 5% 5-fluorouracil cream in patients with AIDS-related Kaposi's sarcoma. All patients have two similar early lesions identified and randomly allocated to treatment with the cream or assessment as the control. The cream is applied once daily for 1 month, and then twice daily until 3 months, unless ulceration occurs before this time. Ten patients have been recruited. Three are still applying the cream after 6, 6 and 8 weeks with no response to date. Three patients completed 3 months treatment, two achieving partial responses maintained at 1 month. Four patients did not complete 3 months application. One patient died at 3 weeks, two stopped due to intercurrent opportunistic infection after 6 and 4 weeks, the other patient admitted poor compliance. The patient who stopped at 4 weeks exhibits a partial response maintained at 2 months. Erythema was observed in no patient. Further study of this convenient treatment is recommended to determine whether it has a role in the management of AIDS-related Kaposi's sarcoma.
The effect of radiotherapy on local recurrence in Ewing's sarcoma of bone N.G. Burnet & C.L. Harmer Royal Marsden Hospital, London SW3, UK.
To assess local control, 82 cases of Ewing's sarcoma of bone treated between 1967 and 1986 were reviewed. Forty-four males and 38 females were treated, median age 16 years. Thirty tumours arose in the leg, 15 in the arm, 16 in the pelvis and 21 elsewhere. Size could not be accurately assessed retrospectively. Sixty-two (76%) have relapsed, median time to relapse 12 months. Of the 20 (24%) disease-free, two died from complications of chemotherapy; median follow-up was 40 months but two patients had follow-up of less than 12 months. In addition to the 20 relapse-free patients, 38 relapsed distantly but with local control. Fifty-eight patients (71%) thus achieved local control. Eleven patients suffered local relapse alone, 13 local and distant relapse together. Most patients received both radio-and chemotherapy. Eleven patients received no radiotherapy, 10 no chemotherapy, and one received neither. Eleven patients had surgery, eight narrow excision and three wide clearance by amputation.
Proximal or distal location in a limb had no effect on relapse-free rates, which were similar (27%) for all areas except the pelvis, where only two of 16 (13%) were diseasefree and both died from treatment complications. Four disease-free patients, including the two who died, had distant disease at presentation. However, no patient was salvaged after first relapse. More patients treated after 1976 remain disease-free (30% :9% In this study diameters of ascending and descending thoracic aorta were measured by computerised tomography in 69 patients with lymphoma before and after first line treatment with one of seven different regimes.
Minor increases in aortic diameter over the period were expected due to the ageing process. These increases were greatly exceeded in both ascending and descending aorta after chemotherapy witdh CHOP and CVP regimes. Smaller changes, or changes which were not statistically significant, were noted after MVPP, ChlVPP, ChlVP, mediastinal radiotherapy and radiotherapy plus MVPP.
Cardiovascular damage associated with certain forms of cytotoxic therapy is not confined to the heart but also affects the aorta. This damage to the aorta may clearly be of clinical importance in the older patients receiving chemotherapy. This is illustrated by reference to patients, requiring aortic surgery during or shortly after chemotherapy. Two males, aged 4 and 11 respectively, presented with osteosarcoma of the distal femur, with quite extensive involvement of the femoral shaft. Both were treated with prospective chemotherapy, resection of the whole femur and replacement by a growing endoprothesis. Good tumour response to chemotherapy was seen in both cases. Evidence of continued epiphyseal growth during chemotherapy was noted in gross specimen, fine detail X-ray and histological sections. Several studies have shown increases in the incidence of leukaemia in young persons living close to British nuclear installations. However, no link has been established between the occurrence of such cases of leukaemia and the operation of any of the nuclear plants.
The West Cumbria case-control study seeks to examine whether the increased incidence of lymphoid malignancy, seen in part of the area, can be explained on the basis of increased prevalence of known risk factors, or alternatively establish that the observed cases of malignancy are due, in part, to the activities of the largest nuclear site in the country: Sellafield. Some 97 cases of leukaemia and lym- The bisphosphonate APD (Pamidronate) is a potent inhibitor of osteolysis and the most effective agent for the treatment of hypercalcaemia of malignancy. Long-term inhibition of bone destruction is possible with repeated intravenous administration and this may reduce pain and promote bone healing. In the past the use of oral APD has been limited by upper GI intolerance due to the drug's corrosive properties. We have tested a novel effervescent formulation of oral APD (provided by Ciba-Geigy Pharmaceuticals).
Thirteen patients with bone metastases from breast cancer were studied, eleven with evidence of increased osteolysis (urinary calcium excretion > 0.4 mmol mmol-' creatinine). In vivo 31p MRS provides a non-invasive measurement of cellular phosphorous metabolism. Eight patients with locally advanced breast carcinoma hve been assessed during treatment. Phosphomonoesters (PME) and phosphodiesters (PDE) (precursors and degradation products of phospholipid metabolism respectively) were prominent in all of the tumours. The technique may therefore provide an indirect indicator of cell membrane synthesis and hence replication. Phosphocreatine (PCr), which provides a reserve of high energy phosphate, was undetectable or at a low level in all of the tumours examined. Adenosine triphosphate (ATP) and inoganic phosphate (Pi) were readily detected in all cases providing an indication of the efficiency of cellular bioenergetic metabolism. Five patients were treated with combination chemotherapy, two with tamoxifen and one with external beam irradiation. Three patients responding to chemotherapy demonstrated spectral changes, predominantly reduction of the PME and PDE peaks, bioenergetic changes (ATP, Pi, PCr) were less consistent. In two patients these changes preceded the clinical response. No spectral changes were observed in the remaining two non-responding patients. One of the tamoxifen treated patients showed neither spectral nor clinical response to therapy. The second demonstrated a generalised increase of the NMR signal two weeks after commencing tamoxifen with concomitant increase in tumour blood flow as measured by 99Tcm labelled HMPAO. These changes preceded an increase in the tumour volume and were therefore early markers of disease progression. No spectral changes were observed during treatment in the patient undergoing radical external beam breast irradiation, despite a reduction of tumour volume.
In conclusion we have observed spectral changes which preceded clinically measurable changes in tumour volume. In vivo 31P NMR spectroscopy may therefore provide a sensitive non-invasive method for assessing therapeutic response in the treatment of breast cancer. The actuarial incidence of a radiation induced brachial plexus injury for the whole group was 4.9% at 6 years. No cases were seen in the first 10 months following radiotherapy.
The incidence rises between 1 and 4 years and then starts to plateau. When the large fraction size group is compared with the small fraction size group the incidence at 6 years is 5.9% and 1.0% respectively (P <0.1). Two different treatment techniques were used in this group but were not found to contribute to the probability of developing plexus injury. When treating cancer of the head and neck, irradiation of the neck is often given using a single anterior field with a central block, 2 cm wide, to shield the spinal cord and larynx. The aim of this study was to look at the doses received by the different lymph node groups in the neck, the effect of the central block, and the dose distribution at the match line of an anterior neck field and a lateral field, such as that used in treating nasopharyngeal carcinoma.
Five patients, with different sized necks, were CT scanned in the treatment position. The position of the various neck node groups, i.e. the anterior cervical chain including the scalene nodes, the posterior chain, and the retropharyngeal nodes, were marked on each CT slice. Plans were done at 1 cm intervals using the TARGET and experimental JCPLAN systems. Doses to nodes in the posterior cervical chain were between 70 and 80% of the applied dose when the anterior field is given using a 6 MV beam. Other beam combinations give a better distribution: either a single anterior 10 MV or a mixture of 60 MV and 25 MV anterior beams, or the addition of a posterior field to the 6 MV anterior field.
Scalene nodes at the inferior end of the anterior cervical chain may be shielded by the central block if it is 2 cm wide throughout its length.
These findings may be important when treating cancers of the head and neck where there is a high incidence of metastatic disease in the posterior cervical nodes, such as nasopharyngeal carcinoma. To investigate the effects of malignancy, radiotherapy and smoking on mucosal immunity, the flow rate and immunoglobulin (Ig) profile of pure parotid saliva were measured in both healthy controls and patients with squamous carcinoma of head and neck mucosa. The controls were either smokers (47) or non-smokers (30). The patients were either untreated (30) or previously irradiated (30). In addition paired samples were obtained from 14 patients prior to and on completion of radical radiotherapy.
It was found that smoking significantly decreased salivary IgA and increased IgM (P < l0-5). This effect was related to the number of cigarettes smoked (P < 10-5), and reversed in former smokers. Similarly salivary IgA was significantly decreased, and IgM increased in cancer patients compared with controls, but this finding did not change with treatment, although flow rate increased with radiotherapy.
The observed changes in cancer patients may simply reflect the fact that most were smokers. The possibility that smoking-induced mucosal immunodeficiency may be an important aetiological factor in upper aerodigestive tract cancer merits further investigation. IE (n = 24) and IIE (n = 32) non-Hodgkin's lymphoma (NHL) of the palatine tonsil registered with the British National Lymphoma Investigation (BNLI) were treated primarily with radiotherapy alone.
The sex ratio was equal. Mean age overall was 59 (range 25-89). Overall CR rate at 3 months post-treatment was 75% (42/56) (stage IE 83% (20/24), IIE 72% (23/32)). Thirteen patients failed to enter CR; two failed within the radiation field, one 'in-field' and generalised, two in an adjacent site, five intra-abdominally, one in the groin, one at unspecified site, and one died of CVA at 2 months. Fourteen patients relapsed after achieving CR, sites of relapse were: intra-abdominal (7), adjacent (2), 'in-field' (1), bone (2), CNS (1) and groin (1). Only four patients were either not controlled locally by RT or experienced first relapse in the irradiated area.
Twenty-three patients have died. In 16 instances (70%), death was either due to NHL or the patient had active disease when last seen.
There was a significant correlation between survival and age at presentation, with younger patients faring better. A significant difference in disease-free survival existed between stages I and II in favour of stage I, but there was no significant difference in survival overall.
A feasibility study of .4 years with a range of 22-79 years. The male to female ratio was 2.6:1. Of these 29 patients, eight had undergone either radical excision of tumour or palliative bypass procedure. In the remainder biliary stents were inserted to relieve obstructive jaundice. Nine patients were considered to be in such poor condition that radiotherapy was not indicated. The radiotherapy regimes used were as follows: external beam therapy alone (six patients); external beam therapy combined with interstitial therapy (eight patients); and interstitial therapy alone (six patients). Brachytherapy was given in the form of iridium-192 wire inserted via a percutaneous transhepatic catheter.
Of the 20 patients treated by radiotherapy, follow-up data are available for 19. Ten patients have died, with a mean survival of 9 months after radiotherapy. Nine patients are alive with a mean follow up of 10 months.
The technique of intracavitary treatment for cholangiocarcinoma will be described and the data on this series of 29 patients presented. In conventional radiotherapy, smaller tumours are invariably more radiocurable than larger ones. In targeted radiotherapy, the lesser cell content of smaller tumours may be offset by reduced efficiency of absorption of radioactive disintegration energy from radionuclides which are long range P-emitters.
We have used a mathematical model based on Poisson statistics to evaluate relative curability of tumours with cell content from 10' to 10'0 cells using targeted '"'I or 90Y. The analysis made use of available microdosimetric data on energy absorption by very small spheres. Computer simulations were carried out for a wide range of therapeutic radionuclide activities (e.g. 0-1000 mCi '3'I) for varying specific uptake of activity by tumour cells (e.g. 0.00001-0.001 g-') and differing clonogenic fraction (e.g. 0.05-0.5). The results show that, for each radionuclide, there is a tumour size region within which tumour radiocurability is maximum. For '"II, the optimal cure region is close to approximately 106 cell content, while for 9Y it is close to approximately 108 cell content. Above this cell content, curability decreases due to increasing cell number. Below thissalivary tumours, of which eight were recurrent. The policy was to treat all untreated high-grade tumours (HGT) by preoperative radiotherapy. Low-grade tumours (LGT) (some muco-epidermoid, all adenoid cystic and acinic cell carcinomas) were treated by surgery alone. In both groups the purpose of surgery was to achieve tumour clearance while preserving the stem and any branches of the facial nerve not already destroyed. Of 10 patients with HGT, six had complete facial palsy at presentation due to tumour. Of eight patients with LGT, two had partial facial palsy due to previous surgery. Following surgery only one patient suffered further permanent deterioration of facial nerve function. The decision to perform radical neck dissection (RND) was taken at the time of surgery by biopsy and frozen section of the jugulo-digastric node which was positive in five patients, only one of whom had palpable matastatic cervical lymphadenopathy. Five patients have died from metastases 8-47 months from initial presentation, and one has local recurrence after surgery: all had HGT. Eight patients with malignant melanoma presented with pre-auricular node metastases. Diagnosis was confirmed by cytology and each patient was treated by superficial parotidectomy and RND. Cervical nodes were positive in six. Four patients have died of metastatic disease and one has local recurrence. Effective regional node dissection for palliation of melanoma is recommended. 
